Vital Therapies, Inc. — Q3 2014 Form 10-Q
Entity note: The filing identifies Vital Therapies, Inc. as the registrant; it does not identify Immunic, Inc. The unaudited quarter and nine-month periods ended September 30, 2014.
Business context
Vital Therapies is a clinical-stage biotherapeutic company developing the ELAD System, an extracorporeal, cell-based therapy for acute liver failure. ELAD was in Phase 3 development, with no approved products and no revenue from planned principal operations.
Financial performance and liquidity
- Revenue and margins: No product revenue was reported. With no revenue, operating margins are not meaningful.
- Q3 expenses and loss: Research and development expense was $10.2 million, up 66% year over year, primarily due to increased Phase 3 trial activity. General and administrative expense was $2.6 million, down 15%. Total operating expenses were $12.8 million; net loss was $12.8 million, versus $7.0 million in Q3 2013.
- Nine-month results: R&D expense was $28.6 million, up 102%; G&A was $7.7 million, up 10%; and total operating expenses were $36.3 million, up 72%. Net loss was $33.7 million versus $22.5 million. Net loss attributable to common stockholders was $42.9 million versus $26.6 million, including preferred-stock accretion and deemed-dividend effects.
- Cash flow: Operating activities used $30.4 million in the first nine months, compared with $18.5 million in the prior-year period. Investing activities used $1.9 million; financing activities provided $73.2 million, mainly from the IPO and preferred-stock financing.
- Liquidity and obligations: September 30 cash and cash equivalents were $79.1 million, with $1.5 million of restricted cash. Current assets were $82.6 million and current liabilities $8.5 million. The filing reports no borrowings or debt balance; other long-term liabilities were $0.3 million.
- Capital raises: The April/May IPO generated $51.9 million in net proceeds, as described in MD&A. A follow-on offering completed after quarter-end generated approximately $32.8 million in net proceeds after the partial underwriters’ option exercise in November.
Changes and notable items
- All outstanding preferred stock converted to common stock in connection with the April 2014 IPO. The company reported 21.8 million common shares outstanding at September 30 and 23.8 million at November 7.
- Compared with the prior-year quarter, operating expenses rose 40%, driven by clinical development; the prior-year quarter’s other income included a $2.2 million gain from revaluation of future purchase rights, which did not recur in Q3 2014.
- The company adopted the accounting update eliminating development-stage-entity reporting and removed inception-to-date disclosures.
Outlook, trials, and risks
- Management expected increasing operating losses and expenses for at least several years. It estimated that September-quarter cash plus the subsequent offering proceeds would fund operations into Q4 2016, assuming no significant commercial-infrastructure buildout. The forecast was intended to cover enrollment and topline data for VTI-208 and VTI-210 (assuming a 150-subject VTI-210 trial) and the VTI-212 Phase 2 trial.
- As of November 12, 2014, VTI-208 had enrolled 175 of 200 planned subjects, with 51 sites open. VTI-210’s modified protocol was expected to begin enrollment in Q4 2014; nine sites were open. The first VTI-212 patient had been enrolled in a trial planned for 40 subjects.
- Management highlighted clinical, regulatory, manufacturing, funding, and commercialization uncertainty. The FDA had raised concerns about VTI-208’s open-label design, potential confounding in standards of care, and whether trial evidence could support approval; prior trials had not shown statistically significant improvement in their primary survival endpoints.
- Material weaknesses in internal control over financial reporting remained under remediation. Management concluded disclosure controls and procedures were not effective as of September 30, 2014.
- The company reported no current material litigation. Other risks include reliance on single-source suppliers, clinical-trial enrollment and safety, regulatory approval, reimbursement and pricing, and future capital needs.
Investor verification priorities
- Confirm current enrollment, trial design, endpoints, timing, and topline-data expectations for VTI-208, VTI-210, and VTI-212.
- Assess the assumptions behind the stated cash runway, including trial costs, offering proceeds, and any commercial-infrastructure spending.
- Review subsequent filings for follow-on offering final costs and proceeds, share dilution, and changes in outstanding shares or lock-up restrictions.
- Track remediation of the disclosed material weaknesses and whether controls become effective.
- Monitor FDA and other regulator feedback, supplier continuity, and evidence supporting safety and efficacy.